Videos

Charles Fuchs, MD: Impeding RAS Mutation Testing

April 26th 2016

Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

April 26th 2016

Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies

April 26th 2016

Charles Fuchs, MD: Clinical Importance of RAS Mutations

April 26th 2016

Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer

April 26th 2016

Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab

April 26th 2016

Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing

April 26th 2016

Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing

April 26th 2016

Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC

April 26th 2016

Tanios Bekaii-Saab, MD: RAS Mutations and the Sequence of Therapies

April 26th 2016

Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

April 26th 2016

Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer

April 26th 2016

Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer

April 26th 2016

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

April 26th 2016

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1

April 26th 2016

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD

Charles Fuchs, MD: Mutations in Colorectal Cancer

April 26th 2016

Charles Fuchs, MD: Experience With Patients on Bevacizumab Plus Chemotherapy

April 26th 2016

Charles Fuchs, MD: Treatment Toxicities and Quality of Life

April 26th 2016

Charles Fuchs, MD: Chemotherapy Side-Effects

April 26th 2016

Charles Fuchs, MD: Bevacizumab Side-Effects

April 26th 2016

Charles Fuchs, MD: Bevacizumab Plus Chemotherapy

April 26th 2016

Charles Fuchs, MD: First-Line Treatments in Unresectable Colon Cancer

April 26th 2016

Tanios Bekaii-Saab, MD: Experience With Patients on Bevacizumab Plus Chemotherapy

April 26th 2016

Tanios Bekaii-Saab, MD: Treatment Toxicities and Quality of Life

April 26th 2016

Tanios Bekaii-Saab, MD: Chemotherapy Side-Effects

April 26th 2016

Tanios Bekaii-Saab, MD: Bevacizumab Side-Effects

April 26th 2016

Tanios Bekaii-Saab, MD: Bevacizumab Plus Chemotherapy

April 26th 2016

Tanios Bekaii-Saab, MD: First-Line Treatments in Unresectable Colon Cancer

April 26th 2016

ER+/HER2-Breast Cancer with Adam Brufsky, MD, PhD and Kimberly Blackwell, MD: Case 2

April 26th 2016

ER+/HER2-Breast Cancer with Adam Brufsky, MD, PhD and Kimberly Blackwell, MD

Adam Brufsky, MD, PhD: Clinical Trial Data Supporting These Choices

April 26th 2016

Videos

Charles Fuchs, MD: Impeding RAS Mutation Testing

Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies

Charles Fuchs, MD: Clinical Importance of RAS Mutations

Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer

Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab

Tanios Bekaii-Saab, MD: Strategies to Increase RAS Testing

Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing

Tanios Bekaii-Saab, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Tanios Bekaii-Saab, MD: RAS Mutations and the Sequence of Therapies

Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

Tanios Bekaii-Saab, MD: RAS Mutations in Metastatic Colorectal Cancer

Tanios Bekaii-Saab, MD: Mutations in Colorectal Cancer

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 1

Charles Fuchs, MD: Mutations in Colorectal Cancer

Charles Fuchs, MD: Experience With Patients on Bevacizumab Plus Chemotherapy

Charles Fuchs, MD: Treatment Toxicities and Quality of Life

Charles Fuchs, MD: Chemotherapy Side-Effects

Charles Fuchs, MD: Bevacizumab Side-Effects

Charles Fuchs, MD: Bevacizumab Plus Chemotherapy

Charles Fuchs, MD: First-Line Treatments in Unresectable Colon Cancer

Tanios Bekaii-Saab, MD: Experience With Patients on Bevacizumab Plus Chemotherapy

Tanios Bekaii-Saab, MD: Treatment Toxicities and Quality of Life

Tanios Bekaii-Saab, MD: Chemotherapy Side-Effects

Tanios Bekaii-Saab, MD: Bevacizumab Side-Effects

Tanios Bekaii-Saab, MD: Bevacizumab Plus Chemotherapy

Tanios Bekaii-Saab, MD: First-Line Treatments in Unresectable Colon Cancer

ER+/HER2-Breast Cancer with Adam Brufsky, MD, PhD and Kimberly Blackwell, MD: Case 2

Adam Brufsky, MD, PhD: Clinical Trial Data Supporting These Choices

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Phase 3 Data Highlight Orca-T’s Clinical Benefits in Heme Malignancies

FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC

ctDNA Assay Offers Prognostic Insights for Immunotherapy-Treated Solid Tumors

ctDNA Refines Risk in Neoadjuvant-Resistant Breast Cancer

Promoting CAR T Access Focuses on Awareness, Capacity, and Economics